These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 20703230

  • 21. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H, Hayashi K, Saruta T.
    J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
    [Abstract] [Full Text] [Related]

  • 22. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
    Azizi M, Ménard J, Bissery A, Guyenne TT, Bura-Rivière A, Vaidyanathan S, Camisasca RP.
    J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
    [Abstract] [Full Text] [Related]

  • 23. [Experience in the use of valsartan with the aim to inhibit progression of kidney failure in patients with chronic glomerulonephritis].
    Shvetsov MIu, Medvedeva TIu, Kozlovskaia NL, Miroshnichenko NG, Okonova EB, Shonichev DG, Rudenko TE, Stavrovskaia EV, Plieva OK.
    Ter Arkh; 2001 Dec; 73(6):55-61. PubMed ID: 11521525
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D.
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [Abstract] [Full Text] [Related]

  • 25. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, Kim MJ.
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [Abstract] [Full Text] [Related]

  • 26. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
    Fujisawa T, Ikegami H, Ono M, Nishino M, Noso S, Kawabata Y, Ogihara T.
    Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
    [Abstract] [Full Text] [Related]

  • 27. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.
    Sugihara M, Miura S, Takamiya Y, Kiya Y, Arimura T, Iwata A, Kawamura A, Nishikawa H, Uehara Y, Saku K.
    Hypertens Res; 2009 Jul; 32(7):625-30. PubMed ID: 19461652
    [Abstract] [Full Text] [Related]

  • 28. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
    Renke M, Tylicki L, Rutkowski P, Wojnarowski K, Lysiak-Szydlowska W, Rutkowski B.
    Scand J Urol Nephrol; 2005 Jul; 39(6):511-7. PubMed ID: 16303729
    [Abstract] [Full Text] [Related]

  • 29. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
    Montanaro D, Gropuzzo M, Tulissi P, Vallone C, Boscutti G, Mioni R, Risaliti A, Baccarani U, Adani GL, Sainz M, Bresadola F, Mioni G.
    Transplant Proc; 2005 Mar; 37(2):991-3. PubMed ID: 15848600
    [Abstract] [Full Text] [Related]

  • 30. Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease.
    Weinberg AJ, Zappe DH, Ramadugu R, Weinberg MS.
    J Hypertens Suppl; 2006 Mar; 24(1):S95-9. PubMed ID: 16601581
    [Abstract] [Full Text] [Related]

  • 31. Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: an open, controlled, randomized study.
    Tylicki L, Renke M, Rutkowski P, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Scand J Urol Nephrol; 2008 Mar; 42(4):381-8. PubMed ID: 19230172
    [Abstract] [Full Text] [Related]

  • 32. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R.
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [Abstract] [Full Text] [Related]

  • 33. Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients.
    Weir MR, Hollenberg NK, Remuzzi G, Zappe DH, Meng X, Parving HH.
    J Hypertens; 2011 Oct; 29(10):2031-7. PubMed ID: 21841500
    [Abstract] [Full Text] [Related]

  • 34. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
    Hasler C, Nussberger J, Maillard M, Forclaz A, Brunner HR, Burnier M.
    Clin Pharmacol Ther; 2005 Nov; 78(5):501-7. PubMed ID: 16321616
    [Abstract] [Full Text] [Related]

  • 35. Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction.
    de Gasparo M, Hess P, Nuesslein-Hildesheim B, Bruneval P, Clozel JP.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):151-8. PubMed ID: 11967807
    [Abstract] [Full Text] [Related]

  • 36. Evaluation of arterial stiffness in morning hypertension under high-dose valsartan compared to valsartan plus low-dose diuretic.
    Takami T.
    Hypertens Res; 2009 Dec; 32(12):1086-90. PubMed ID: 19779491
    [Abstract] [Full Text] [Related]

  • 37. Dual renin-angiotensin system blockade: in patients with single functioning kidney and proteinuria.
    Robles NR, Ruiz Jiménez B, Hernández Gallego R, Ruiz-Calero R, Sánchez Casado E, Cubero JJ.
    Eur J Intern Med; 2009 Mar; 20(2):186-9. PubMed ID: 19327610
    [Abstract] [Full Text] [Related]

  • 38. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.
    González Monte E, Andrés A, Polanco N, Toribio MJ, Santana R, Gutiérrez Martínez E, González J, Ramírez E, Hernández A, Morales E, Praga M, Morales JM.
    Transplant Proc; 2010 Oct; 42(8):2899-901. PubMed ID: 20970564
    [Abstract] [Full Text] [Related]

  • 39. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
    Lacourcière Y, Poirier L, Hebert D, Assouline L, Stolt P, Rehel B, Khder Y.
    Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
    [Abstract] [Full Text] [Related]

  • 40. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D, Glazes R, Kargiannis S, Wernsing M, Kaczor J, Chiang YT, Yen J, Gamboa R, Fomina I.
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.